National leaders in biotechnology venture capital will offer advice to entrepreneurs interested in securing funding at the New Jersey Economic Development Authority’s two-hour panel on Tuesday, January 17, at 4:30 p.m. at the Commercialization Center for Innovative Technologies in North Brunswick. For more information, visit www.njeda.com.

“Early-stage companies are always interested in best practices for raising funds,” EDA Chief Executive Officer Melissa Orsen said. “This event offers them the opportunity to hear directly from some of the top biotechnology VC firms in the country.”

The discussion is co-sponsored by BioNJ, the New Jersey Technology Council, and the HealthCare Institute of New Jersey. Arch Ventures’ Tom Brennan; Flagship Pioneering’s Jason Park; and, Versant Ventures’ Cameron Pitt will answer a variety of funding questions, including: How will venture capitalists fund the next generation of drugs, diagnostics and devices? What should you look out for as an early and emerging commercial biotech company seeking funding?

Brennan is a venture partner at Arch Ventures, where he is involved with all aspects of value creation of early-stage advanced technologies. With $2 billion under management, Arch is one of the largest providers of seed and early-state capital in the United States. Brennan grew up in Northfield, Atlantic County, and graduated from Stevens Institute of Technology.

Park is a principal at Flagship Pioneering, which has $1.8 billion under management and has become one of the nation’s leading venture creation firms in the life sciences. Flagship’s scientific ventures start by exploring unprecedented solutions for unsolved problems representing unproven value opportunities.

Pitt is an associate at Versant Ventures, where he focuses on healthcare investment. The company has $1.9 billion under management and invests across all stages of company development, with an emphasis on the discovery and development of novel therapeutics. Since the firm’s founding, 50 Versant companies have achieved successful acquisitions or initial public offerings.

The event will also give biotechnology companies the chance to visit CCIT, a 46,000-square-foot life sciences incubator that is home to nearly two dozen businesses. It offers 27 wet labs and access to offices, conference rooms, a supportive staff and a variety of additional resources. CCIT is located within the Technology Centre of New Jersey, a 75-acre research park that houses such companies as Chromocell and Orthobond (both of which are CCIT graduates), Allergan, and Merial. Companies interested in touring CCIT should visit www.njeda.com/CCIT or contact Lenzie Harcum at lharcum@njeda.com.

Facebook Comments